3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
12
Active not recruiting
2
Withdrawn
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Lymphoma, T-Cell, Cutaneous
5
Mycosis Fungoides
3
Multiple Myeloma
3
Hodgkin Disease
3
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Stomach Neoplasms
1
Somatostatinoma
1
Sezary Syndrome
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Insulinoma
1
Inflammatory Breast Neoplasms
1
Glucagonoma
1
Gastrinoma
1
Esophageal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Islet Cell
1
Interventions
Cyclophosphamide
4
Prednisone
3
Lenalidomide
3
fludarabine phosphate
2
etoposide phosphate
2
cobomarsen
2
Whole-Body Irradiation
2
Vorinostat
2
Vincristine
2
Stem Cell Transplantation
2
Nivolumab
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Etoposide
2
Doxorubicin
2
Bortezomib
2
Alemtuzumab
2
tazemetostat
1
sargramostim
1
romidepsin
1
poly ICLC
1
plerixafor
1
pegylated granulocyte colony-stimulating factor, human
1
pegfilgrastim
1
pegaspargase
1
liposomal doxorubicin
1
forodesine
1
fludarabine
1
duvelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell
×
romidepsin
×
Clear all
NCT01742793
2020-03-04
RID
Yale University
Phase 1
Terminated
12 enrolled